SBWire

GlobalData's clinical trial report, "Alpha-Mannosidosis Global Clinical Trials Review, H1, 2014" provides data on the Alpha-Mannosidosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Alpha-Mannosidosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Alpha-Mannosidosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

Chagas Disease (American Trypanosomiasis) - Pipeline Review, H1 2014

Chronic Pain - Pipeline Review, H1 2014

GBI Research, has released the pharma report -"Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies". The current Ovarian cancer therapeutics market is dominated by the use of generics - predominately carboplatin and paclitaxel, which are used in combination for the treatment of platinum-sensitive disease (both first-line and recurrent). Initial treatment with platinum-based therapy is usually effective, with approximately 70% of patients entering remission. However, even with extended progression free-survival of 24 months, almost all patients relapse, and after successive periods of remission and relapse either die or progress to platinum-resistant disease, for which the prognosis is poor. There is a clear gap in the market for maintenance therapies to extend the initial high rates of remission, and hopefully stimulate long-term remission in patients. As well as a gap for more effective treatment options in platinum-resistant or refractory patients.

GlobalData's clinical trial report, "Hyperammonemia Global Clinical Trials Review, H1, 2014" provides data on the Hyperammonemia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hyperammonemia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hyperammonemia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, "Verrucous Carcinoma Global Clinical Trials Review, H1, 2014" provides data on the Verrucous Carcinoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Verrucous Carcinoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Verrucous Carcinoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

DBV Technologies - Product Pipeline Review - 2014

Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson's disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.

Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson's disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014

Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson's disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.

Heinkel USA, a company which offers a complete line of centrifuge and vacuum drying technologies, is pleased to announce they will be taking part as exhibitors at the 2014 CPhi China Global Pharmaceutical Sourcing Conference on June 26-28. CPhi China is the number one Pharmaceutical sourcing event in the world, with more than 30,000 visitors from over 100 countries attending the networking event each year. Heinkel USA will be one of the 2,200 exhibitors showcasing their company this year.

InnaVirVax SA - Product Pipeline Review - 2014

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

New Pharmaceuticals market report from Global Markets Direct: "Ischemic Stroke - Pipeline Review, H1 2014"

Recently published research from Global Markets Direct, "Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2014", is now available at Fast Market Research

Fast Market Research recommends "Celsion Corporation - Product Pipeline Review - 2014" from Global Markets Direct, now available

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

New Pharmaceuticals market report from Global Markets Direct: "Malaria - Pipeline Review, H1 2014"

Traumatic Brain Injury - Pipeline Review, H1 2014

Fast Market Research recommends "Diabetic Nephropathy - Pipeline Review, H1 2014" from Global Markets Direct, now available

The Parasitic Partnering 2009-2014 provides understanding and access to the parasitic partnering deals and agreements entered into by the worlds leading healthcare companies.

Fast Market Research recommends "Cerebral Palsy - Pipeline Review, H1 2014" from Global Markets Direct, now available

CEL-SCI Corporation - Product Pipeline Review - 2014